Hemispherx Biopharma, Inc.
(NYSE Amex Equities : HEB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Loading HEB News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.46%73.760.9%$699.22m
AMGNAmgen Inc.
0.50%180.211.1%$562.99m
CELGCelgene Corporation
1.05%137.741.1%$511.41m
REGNRegeneron Pharmaceuticals, Inc.
-1.00%515.922.7%$478.88m
VRTXVertex Pharmaceuticals Incorporated
2.41%163.171.9%$401.70m
BIIBBiogen Inc.
0.53%282.921.2%$362.26m
ALXNAlexion Pharmaceuticals, Inc.
1.53%131.791.9%$271.34m
TSROTESARO, Inc.
2.29%131.9714.7%$172.59m
ILMNIllumina, Inc.
0.45%172.753.5%$161.08m
INCYIncyte Corporation
0.32%134.222.6%$151.82m
EXELExelixis, Inc.
0.89%27.236.5%$148.60m
CLVSClovis Oncology, Inc.
1.61%86.6418.0%$130.90m
BMRNBioMarin Pharmaceutical Inc.
1.76%89.284.4%$127.08m
KITEKite Pharma, Inc.
-0.67%109.1516.1%$120.98m
SRPTSarepta Therapeutics, Inc.
6.06%43.4119.8%$112.50m

Company Profile

Hemispherx Biopharma, Inc. is a biopharmaceutical company, which engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based disorders. Its products include Alferon N Injection and the experimental immunotherapeutic/antiviral Ampligen. Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. Ampligen includes application as a treatment for Chronic Fatigue Syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Philadelphia, PA.